GlassScriptPhysician profile
Frantzchesca Decade
NPI 1164759668
$670.43
in general payments reported to CMS, 2019-2025
11 companies · $38.63 in 2025
The $38.63 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.31 · 2022: $173 · 2023: $212 · 2024: $183 · 2025: $38.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $293.31 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $116.20 | 2023 | Wegovy |
| Ethicon US, LLC | $50.42 | 2022-2024 | Linx Reflux Management System |
| Boston Scientific Corporation | $39.02 | 2024 | Varithena Administration Pack |
| Currax Pharmaceuticals LLC | $34.35 | 2021-2025 | Contrave |
| Daiichi Sankyo INC. | $33.35 | 2021-2023 | Injectafer |
| Medtronic, INC. | $25.60 | 2021 | |
| Olympus America INC. | $22.69 | 2023 | |
| Redhill Biopharma INC. | $21.44 | 2023 | Talicia, Movantik, Aemcolo |
| Cumberland Pharmaceuticals, INC. | $18.20 | 2022 | |
| Endo Pharmaceuticals INC. | $15.85 | 2023 | Nascobal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frantzchesca Decade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.